Washed microbiota transplantation: candidates for a novel strategy for ameliorating autism spectrum disorder

TL;DR

This paper explores a new treatment called Washed Microbiota Transplantation (WMT) for Autism Spectrum Disorder (ASD), which may offer safer and more ethical benefits than current methods.

Contribution

The paper introduces WMT as a novel therapeutic strategy for ASD, emphasizing its safety and ethical advantages over Fecal Microbiota Transplantation (FMT).

Findings

WMT reduces adverse events by removing harmful residues and pro-inflammatory metabolites.

WMT addresses ethical and aesthetic concerns linked to FMT.

WMT offers new potential for ASD treatment based on gut microbiota research.

Abstract

Autism Spectrum Disorder (ASD) is a severe neurodevelopmental disorder with an increasing global incidence, imposing substantial burdens on both society and affected families. The pathogenesis of ASD is complex, involving genetic, environmental, and other factors. Notably, children with ASD often exhibit gut microbiota dysbiosis, and the relationship between gut microbiota and ASD has garnered growing attention. Current treatments for ASD remain limited and unsatisfactory. As an emerging therapeutic approach, Washed Microbiota Transplantation (WMT) reduces undigested food residues, fungi, parasite eggs, and pro-inflammatory metabolites, thereby lowering the incidence of adverse clinical events. WMT also addresses ethical and aesthetic concerns associated with Fecal Microbiota Transplantation (FMT), enhances treatment safety, and offers new hope for ASD management. This review integrates global literature to analyze the latest findings on ASD epidemiology, societal impacts, existing therapies, and clinical research on WMT, aiming to provide scientific evidence for the clinical application of WMT in ASD treatment.

Figures